Recommended
Recommended
More Related Content
Similar to Ose pharma cp july 3 2012 ve
Similar to Ose pharma cp july 3 2012 ve (20)
Recently uploaded
Recently uploaded (20)
Ose pharma cp july 3 2012 ve
- 1. OSE PHARMA A NEW PLAYER IN PHASE III IN LUNG CANCER WITH AN INNOVATIVE CANCER THERAPEUTIC VACCINE Orphan Synergy Europe-‐ Pharma (OSE Pharma Paris), is preparing fundraising focused on an international clinical phase III for a cancer therapeutic vaccine fighting lung cancer. Paris, France, July 2, 2012 -‐ Dominique Costantini, M.D, and Emile Loria, M.D, health experienced professionals, announce the creation of OSE Pharma, an innovative new biopharmaceutical company developing advanced phase III clinical, first-‐ in-‐class, breakthrough innovative products for Orphan severe lung diseases. OSE Pharma has in-‐licensed a cancer therapeutic vaccine program for international development and European rights in lung cancer, the main cause of mortality by cancer in the world (cf p2). Recognized internationally in the Biopharma industry, who they have acquired a complementary expertise, Dominique Costantini and Emile Loria have respectively successfully created, managed business operations in public companies, in Europe the company BioAlliance (Euronext) and the US company Epimmune (Nasdaq). “Starting this new venture, is based first on the interest of this therapeutic vaccine targeting simultaneously various Tumor antigens, an important choice when we know the heterogeneity of these antigens. The clinical phase II results conducted in severe advanced lung cancer (mainly metastatic Non Small Cell lung cancer with failure of previous lines of treatment) established correlation between survival and immune response covering more than one Tumor Antigens (John Neimunatis -‐ Mary Crowley oncology hospital -‐Dallas-‐ and the other US investigators of the phase 2 trial) commented Dominique Costantini, M.D. CEO of OSE-Pharma. The EP2101 safety and the long term survival are very interesting when the need of new treatment options is clearly established for advanced lung cancer. This phase III priority is the basis of our financing round”. Company’s lead product EP2101 is an active cancer immunotherapy or a cancer therapeutic “vaccine”. It is based on proprietary 10 multi-‐epitopes (small peptides) targeting 5 main Tumor Associated antigens expressed in various tumors. Emile Loria was conducting this epitope program until clinical phase II. OSE-‐ Pharma has established an US epitopes expert team preparing the phase III program. The original EP2101 combination provides Cytotoxic T lymphocytes responses and synergic immune responses versus the 5 Tumor Associated Antigens. EP2101 overcomes “tolerance” (tolerance is an immune response failure because tumor antigens are often shared with normal tissues). These selected epitopes are a combination of wild type and modified analogs increasing binding to receptors (HLA A2) and then becoming able to attack cancer tumor cells of HLA A2 patients. The Cytotoxic T Lymphocytes response is dependent of HLA A2 tissue binding and EP2101 patient responders are HLA A2 positive. OSE Pharma Société anonyme à Conseil d’Administration au capital social de 526 500 euros Siège social : Pépinière Paris Santé Cochin - 29bis rue du Faubourg Saint Jacques 75 014 Paris RCS Paris 479 457 715
- 2. OSE PHARMA A NEW PLAYER IN PHASE III IN LUNG CANCER WITH AN INNOVATIVE CANCER THERAPEUTIC VACCINE COMPANY PROFILE : OSE Pharma an innovative clinical stage (Phase III status) biopharmaceutical company has established its corporate headquarters in Paris Hospital Cochin (Pépinière Paris Santé Cochin), France. OSE Pharma founded in May 2012, is focused on targeting severe and orphan pulmonary diseases, this medico-‐economic model is based on protection and acceleration of development for drugs significantly improving treatment options for patients with unmet medical needs. OSE lead product EP2101 has completed a Phase II clinical trial in non-‐small cell lung cancer HLA A2 positive patient responders. The multi-‐epitopes cancer vaccine (small peptides) are tumor-‐specific CTL (cytotoxic T Lymphocytes) epitopes selected from 5 tumor-‐associated antigens (HER2/neu; P53; CEA; MAGE2; MAGE3). These 5 Tumor associated antigens are for poor prognosis when overexpressed alone and increasing when associated. The OSE epitopes platform benefits also of clinical phase I/II results in colon cancer and could be applied for other cancers with the same Tumors antigens. The company is also preparing a new independent clinical project in Cystic fibrosis, an orphan genetic disorder with progressive lung damages. Lung cancer Lung cancer is the leading cause of cancer death in the world. More people die of lung cancer than of colon, breast and prostate cancers combined. According to the World Health Organization, lung cancer (non-‐small cell, NSCLC, and small cell type) affects more than 1.2 million patients a year, with around 1.1 million deaths annually and around 500,000 in the U.S., Europe and Japan. About 85 percent of all lung cancers are the non-‐small cell type. Further, only about 15 percent of people diagnosed with NSCLC survive this disease after five years. The majority of patients are with advanced stage disease at diagnosis: stage IIIB invasive or Stage IV metastatic). Despite aggressive treatments, the 5-‐year relative survival rates are about 24% for patients with regional disease and less than 4% for patients with distant disease. Contacts OSE Pharma SA H&B Communication Dominique Costantini, CEO Florence Portejoie dominique.costantini@osepharma.com +33 1 58 18 32 58 / +33 6 88 84 81 74 Mob +33 6 13 20 77 49 f.portejoie@hbcommunication.fr Anne Hardy +33 1 58 18 32 51 / +33 6 13 56 23 96 a.hardy@hbcommunication.fr OSE Pharma Société anonyme à Conseil d’Administration au capital social de 526 500 euros Siège social : Pépinière Paris Santé Cochin - 29bis rue du Faubourg Saint Jacques 75 014 Paris RCS Paris 479 457 715